Masimo (NASDAQ:MASI) Issues Q3 Earnings Guidance

Masimo (NASDAQ:MASI) issued an update on its third quarter earnings guidance on Tuesday morning. The company provided EPS guidance of $0.81-0.86 for the period, compared to the consensus EPS estimate of $0.84. The company issued revenue guidance of $495-515 million, compared to the consensus revenue estimate of $502.87 million. Masimo also updated its FY 2024 guidance to 3.800-4.000 EPS.

Masimo Stock Performance

Shares of NASDAQ:MASI traded up $0.21 during midday trading on Friday, hitting $144.22. The company’s stock had a trading volume of 388,470 shares, compared to its average volume of 672,529. The stock has a market capitalization of $7.67 billion, a price-to-earnings ratio of 97.97 and a beta of 0.99. The stock’s 50 day simple moving average is $128.95 and its 200 day simple moving average is $125.27. Masimo has a fifty-two week low of $75.36 and a fifty-two week high of $153.93. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.15 and a current ratio of 2.09.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.09. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The company had revenue of $496.30 million for the quarter, compared to the consensus estimate of $493.92 million. During the same period last year, the business posted $0.62 earnings per share. The firm’s revenue was up 9.0% compared to the same quarter last year. As a group, research analysts anticipate that Masimo will post 3.88 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on MASI shares. Piper Sandler reiterated an “overweight” rating on shares of Masimo in a research note on Friday, October 18th. BTIG Research increased their target price on shares of Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research note on Friday, September 20th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Masimo presently has a consensus rating of “Moderate Buy” and a consensus price target of $145.33.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.